{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:58:22Z","timestamp":1790848702711,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>\n                    Lupus nephritis (LN) is more common and often more aggressive in children than in adults, yet most randomized trials informing current LN management have enrolled adults. The 2024 American College of Rheumatology (ACR) guideline is the first ACR guideline on lupus nephritis to explicitly state that its recommendations apply to both adults and children\n                    <jats:bold>,<\/jats:bold>\n                    although its evidence base remains largely adult-derived. This review uses the 2024 ACR guideline as an organizing framework, cross-referenced with the 2024 KDIGO and 2025 EULAR recommendations, to examine which aspects of LN management translate effectively to pediatric practice and which require caution. We review the diagnostic pathway, including screening, kidney biopsy, and ISN\/RPS classification, as well as therapeutic strategies, including the shift from sequential dual therapy to upfront triple therapy, response targets, class-specific treatment, and selection between belimumab and calcineurin inhibitors. We then examine areas where pediatric evidence remains limited, particularly glucocorticoid dosing, long-term biologic safety, fertility and growth, and transition to adult care. While the fundamental principles of LN management are largely age-agnostic, many quantitative recommendations are not. Steroid dosing, long-term treatment exposure, and developmental consequences remain important pediatric-specific considerations that current guidelines cannot fully address. We conclude by highlighting the pediatric evidence available to date and the need for dedicated pediatric trials to replace adult-derived extrapolation with child-specific evidence.\n                  <\/jats:p>","DOI":"10.3389\/fped.2026.1970903","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:43:25Z","timestamp":1790847805000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Translating the 2024 ACR lupus nephritis guidelines to pediatric practice"],"prefix":"10.3389","volume":"14","author":[{"given":"Minh Dien","family":"Duong","sequence":"first","affiliation":[{"name":"Division of Pediatric Nephrology, Norton Children\u2019s Hospital, University of Louisville School of Medicine","place":["Louisville, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quang","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Missouri","place":["Columbia, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, Norton Children\u2019s Hospital, University of Louisville School of Medicine","place":["Louisville, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/acr.25528","article-title":"2024 American college of rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis","volume":"77","author":"Sammaritano","year":"2025","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"B3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ard.2025.09.007","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update","volume":"85","author":"Fanouriakis","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1136\/annrheumdis-2016-210960","article-title":"European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1136\/annrheumdis-2017-211898","article-title":"European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-025-00653-y","article-title":"Lupus nephritis","volume":"11","author":"Parodis","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3390\/medicina59101841","article-title":"Lupus nephritis in children: novel perspectives","volume":"59","author":"Pennesi","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.kint.2025.05.039","article-title":"Childhood-onset lupus nephritis: unique aspects and challenges in management","volume":"108","author":"Chan","year":"2025","journal-title":"Kidney Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00467-020-04686-1","article-title":"Kidney outcomes for children with lupus nephritis","volume":"36","author":"Oni","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s00467-022-05848-z","article-title":"How common is chronic kidney disease in children with lupus nephritis?","volume":"38","author":"Wenderfer","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1007\/s00467-025-06718-0","article-title":"Childhood-onset lupus nephritis: long-term outcomes and their predictors","volume":"40","author":"Chan","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/IJNRD.S405789","article-title":"New insights on childhood lupus nephritis","volume":"18","author":"Marchi-Silva","year":"2025","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"keag223","DOI":"10.1093\/rheumatology\/keag223","article-title":"The 2026 British society for rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus","volume":"65","author":"Md Yusof","year":"2026","journal-title":"Rheumatology (Oxford)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12969-015-0024-x","article-title":"Practice patterns and approach to kidney biopsy in lupus: a collaboration of the midwest pediatric nephrology consortium and the childhood arthritis and rheumatology research alliance","volume":"13","author":"Wenderfer","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1007\/s00467-022-05859-w","article-title":"Does kidney biopsy in pediatric lupus patients \u201ccomplement\u201d the management and outcomes of silent lupus nephritis? Lessons learned from a pediatric cohort","volume":"38","author":"Mannemuddhu","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1007\/s00467-025-06737-x","article-title":"Silent lupus nephritis: a pediatric center experience of baseline kidney biopsies and review of the published evidence","volume":"40","author":"Laestadius","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10067-016-3491-7","article-title":"Treatable renal disease in children with silent lupus nephritis detected by baseline biopsy: association with serum C3 levels","volume":"36","author":"Wakiguchi","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the international society of nephrology\/renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","article-title":"Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial","volume":"79","author":"Brunner","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1177\/0961203312458466","article-title":"Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial","volume":"21","author":"Sundel","year":"2012","journal-title":"Lupus"},{"key":"B27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/art.41930","article-title":"International consensus for the dosing of corticosteroids in childhood-onset systemic lupus erythematosus with proliferative lupus nephritis","volume":"74","author":"Chalhoub","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/acr.21558","article-title":"Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus","volume":"64","author":"Mina","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1007\/s00467-024-06654-5","article-title":"The unique challenges of childhood-onset systemic lupus erythematosus and lupus nephritis patients: a proposed framework for an individualized transitional care plan","volume":"40","author":"Renson","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1177\/0961203315573346","article-title":"Therapeutic plasma exchange in paediatric SLE: a case series from India","volume":"24","author":"Giri","year":"2015","journal-title":"Lupus"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1970903\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:43:26Z","timestamp":1790847806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1970903\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":30,"alternative-id":["10.3389\/fped.2026.1970903"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1970903","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1970903"}}